Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs FirstEnergy Corp. (FE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs FirstEnergy Corp. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while FirstEnergy Corp. trades at $49.5 (market cap $28.01B). The key difference: FirstEnergy Corp. is far larger — about 3.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and FirstEnergy Corp. pays a 3.84% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | FE | |
|---|---|---|
Market Cap | $8.04B | $28.01B |
Sector | Health | Utilities |
52-Week High | $339.75 | $51.91 |
52-Week Low | $241.71 | $40.30 |
Enterprise Value | $7.85B | $56.02B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
FirstEnergy Corp. (FE) trades at $48.43, up 1.06% on the day, with a bullish technical signal supported by moving averages. The stock shows steady revenue growth, reaching $15.09B in 2025, and maintains a net income margin of 6.86%. Analyst consensus is a Buy with a $52.00 price target, reflecting optimism around grid investments and data center demand. Recent news highlights FE's strategic positioning amid rising energy needs and infrastructure upgrades.
Outlook is positive due to strong fundamentals and growth initiatives, but risks include high debt levels and regulatory pressures. The stock offers potential upside from current levels, supported by earnings beats and institutional confidence, though investors should monitor cash flow trends and execution of capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
